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In patients with pseudomyxoma peritonei or peritoneal mesothelioma, direct extension of disease through the hemidiaphragm
may result in an isolated progression of tumor within the pleural space. We monitored the intrapleural and plasma levels of
mitomycin C and doxorubicin by HPLC assay in order to determine the pharmacokinetic behavior of this intracavitary use of
chemotherapy. Our results showed a persistent high concentration of intrapleural drug as compared to plasma concentrations.
The increased exposure for mitomycin C was 96, and the increased exposure for doxorubicin was 241. When the clearance of
chemotherapy from the thoracic cavity was compared to clearance from the abdomen and pelvis, there was a considerably more
rapid clearance from the abdomen as compared to the thorax. The pharmacologic study of intrapleural chemotherapy in these
patients provides a strong pharmacologic rationale for regional chemotherapy in this group of patients.
1.Introduction
In a majority of patients, the instillation of chemotherapy
into the pleural space is a palliative treatment designed to
reduce or eliminate debilitating accumulations of peritoneal
ﬂuid. In these patients, disease outside of the pleural space
precludes any reasonable attempt to deﬁnitively resect the
cancer within the pleural space. An exception to this is
pleural mesothelioma, where the thoracic surgeon performs
a pleurectomy and decortication of the lung in an attempt to
achievelong-termsurvivalinpatientswithalimitedextentof
pleural mesothelioma. Also, some diseases may progress by
direct extension through the hemidiaphragm and involve the
thoracic cavity. If disease control within the abdomen can be
achieved with cytoreductive surgery combined with hyper-
thermic intraperitoneal chemotherapy (HIPEC), deﬁnitive
treatment of intrapleural progression may be of long-term
beneﬁt to the patient. Diseases where pleural extension
of an intraabdominal disease has been reported include
pseudomyxoma peritonei [1], peritoneal mesothelioma, and
epithelialovariancancer.Intheseclinicalsituations,apatient
musthavediseasecontroldemonstratedwithintheabdomen
and pelvis. Also, prior to the administration of intrapleural
chemotherapy, a thoracic cytoreduction (pleurectomy and
decortication) is performed in an attempt to remove all
visible evidence of the malignant disease. In this paper, we
report on the pharmacology of hyperthermic intrathoracic
chemotherapy (HITOC) in patients with pseudomyxoma
peritonei or peritoneal mesothelioma that had gained en-
trance to the chest through the hemidiaphragm. The chem-
otherapy agents studied are mitomycin C and doxorubicin.
2.MaterialsandMethods
Permission to accumulate and analyze these data was
obtained from the Ethics Committee at our institution.
Patients undergoing pleurectomy and decortication followed
by intrapleural chemotherapy for thoracic extension of
pseudomyxoma peritonei and pleural mesothelioma were
studied. These patients were identiﬁed through a prospective
clinical database. The clinical management of these patients
was as follows. Disease control within the abdomen and
pelvis was determined over a minimum six-month time
intervalusingabdominalandpelvicCTscans.Diseasewithin2 Gastroenterology Research and Practice
the thoracic space was shown to progress over this time
interval. After obtaining consent, the patients were taken to
the operating room for a thoracotomy [2]. The extended
right or left thoracotomy was accompanied by a resection of
the seventh rib. First, a complete parietal peritonectomy was
performed. Then, a partial visceral pleurectomy was per-
formed, only removing pleura that was invaded by the
malignant process. The visceral pleura within the pul-
monary ﬁssures was also carefully cytoreduced. Following
completion of the cancer resection, the thoracic cavity was
irrigated with copious warm saline solution and meticulous
hemostasis obtained. The skin at the anterior and posterior
extent of the thoracotomy incision was sutured shut with a
running skin suture. The skin edges in the mid-portion of
the chest cavity were elevated on a self-retaining retractor
(Thompson Surgical Instruments, Traverse City, MI) in
order to maintain a reservoir within the thoracic space.
For infusion of chemotherapy solution, a Tenckhoﬀ catheter
was placed over the edge of the thoracotomy incision and
secured by a suture. For drainage, a single 28 French straight
thoracostomy tube was inserted through an intercostal space
at the level of the hemidiaphragm posteriorly and directed
up towards the apex of the chest. The chemotherapy solution
was heated and repeatedly circulated by a hyperthermia
pump (Belmont Instrument Corporation, Billerica, MA).
Temperature of the chemotherapy solution was between 41
and 43◦C within the hemithorax. During this dissection,
the lung was maintained partially collapsed through the use
of a double-lumen tube; the lung was allowed to inﬂate
approximately half of its volume for the duration of the
HITOC.
The patients received hyperthermic chemotherapy using
mitomycin C at 15mg/m2, doxorubicin at 15mg/m2,a n d5 -
ﬂuorouracilat400mg/m2 withleucovorinat20mg/m2 given
intravenously.
The concentration of mitomycin C and doxorubicin
within the pleural ﬂuid and plasma was determined at 15-
minute intervals. HPLC assay was used to determine the
concentration as described elsewhere [3, 4].
The carrier solution for the chemotherapy was 1.5%
dextrose peritoneal dialysis solution. The chemotherapy was
diluted in 2 liters of this carrier solution prior to instillation
into the thoracic cavity through the Tenckhoﬀ catheter.
All data presented on the graphs are +1 standard de-
viation. Calculations of area under the curve (AUC) and
subsequentAUC ratios wereobtained using GraphPadPrism
analyses (GraphPad Software, Inc., La Jolla, CA).
For comparison of HITOC pharmacokinetics with hy-
perthermicintraperitonealchemotherapy(HIPEC) pharma-
cokinetics, data from intraperitoneal and plasma drug con-
centrations in 25 consecutive patients were utilized. These
patients were treated during the approximate time period as
the patients receiving HITOC.
3. Results
For mitomycin C pharmacokinetics, three patients were
available for study. All three patients had pseudomyxoma
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Figure 1: Pharmacokinetic study of mitomycin C instilled into
the thoracic space following pleurectomy and decortication for
pseudomyxoma peritonei spread by direct extension through the
hemidiaphragm.Thechemotherapysolutionwasmaintainedat41–
43◦Cbycirculatingthechemotherapyﬂuidthroughahyperthermia
pump.
peritonei in the pleural space, and all three had a com-
plete visible removal of disease at the time of thoracic
cytoreduction. Two had a right thoracotomy and one had
left-sided disease. Figure 1 shows the area under the curve
concentration times, time for the pleural ﬂuid and for the
plasma. The area under the curve pleural ﬂuid to plasma
ratio was 96 ± 41 over the 90 minutes. During the HITOC,
41 ± 3 percent of the total mitomycin C was absorbed from
the thoracic space into the body compartment.
For comparison of HITOC mitomycin C clearance with
HIPEC mitomycin C clearance, we used data from 25
patientswhosepseudomyxomawasconﬁnedtotheabdomen
and pelvis. The mitomycin C was used at 15mg/m2 and
was diluted in 3 liters of 1.5% dextrose peritoneal dialysis
solution. Temperature within the peritoneal space was 41
to 43◦C. Figure 2 shows the percentage of mitomycin C
absorbed from the peritoneal space as compared to the pleu-
ral space. Approximately half of the amount of mitomycin
C was absorbed from the pleural space as compared to the
peritoneal space.
Figure 3 shows the area under the curve for pleural
doxorubicinandforplasmadoxorubicinin4patientstreated
with HITOC doxorubicin at 15mg/m2 in 2 liters of 1.5%
dextrose peritoneal dialysis solution. Two patients had pseu-
domyxoma peritonei and two had peritoneal mesothelioma.
All patients had complete visible removal of disease at the
time of thoracic cytoreduction. The area under the curve
ratio was 241 ± 83.
In Figure 4, the percent of drug absorbed in 4 patients
with HITOC with doxorubicin are compared to 25 patients
who had HIPEC with doxorubicin. Seventy-two percent of
this drug was absorbed at 90 minutes with intrapleuralGastroenterology Research and Practice 3
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Figure 2: Percent mitomycin C absorbed from the chest cavity
as compared to the peritoneal cavity following intrathoracic
or intraperitoneal chemotherapy treatment. The chemotherapy
solution in both groups of patients was maintained between 41
and 43◦C by circulating the chemotherapy solution through a
hyperthermia pump.
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Figure 3: Pharmacokinetic study of doxorubicin in 4 patients who
had drug instillation into the thoracic cavity. The chemotherapy
solution was maintained between 41 and 43◦Cb yc i r c u l a t i o n
through a hyperthermia pump.
administration, and 90% was absorbed with intraperitoneal
administration.
4. Discussion
Intrapleural chemotherapy continues to be well used pallia-
tively in order to control debilitating and unrelenting pleu-
raleﬀusions from cancer. In this current application of intra-
pleural chemotherapy, the patient population was diﬀerent
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Figure 4: Percent doxorubicin absorbed from the pleural space
as compared to the peritoneal cavity following intrathoracic or
intraperitoneal chemotherapy treatment. The chemotherapy solu-
tion was maintained between 41 and 43◦C by circulation through a
hyperthermia pump.
in that no other known sites of disease were present in
our patients. Therefore, the goal of the HITOC treat-
ment was a curative one. The intrapleural chemotherapy
administration was preceded by a thoracic cytoreduction of
both parietal and involved visceral pleura. The goal of the
cancer pleurectomy and decortication was to remove all
visible evidence of disease. The role of the HITOC was to
eliminate the microscopic residual disease that cannot be
removed by cancer surgery. This strategy has been shown
to be eﬀective for peritoneal metastases from appendiceal
malignancy, colorectal cancer, and peritoneal mesothelioma
[5]. The rationale for this treatment within the chest cavity is
the same as that within the peritoneal space.
4.1. Pharmacologic Advantage of Hyperthermic Intrathoracic
Chemotherapy. Our data from patients treated with mito-
mycin C and with doxorubicin clearly show that the phar-
macologic advantage of intracavitary chemotherapy exists
within the thoracic space. This should result in a marked
therapeutic beneﬁt if the residual disease is of minimal
extent so that the intrathoracic chemotherapy can penetrate
the cancer cells. Entrance into the tissues surrounding the
thoracic cavity is by simple diﬀusion [6]. An area under
the curve ratio for mitomycin C of 96 ± 41 over the 90
minutes conﬁrms the pharmacologic advantages of regional
chemotherapy administration. Likewise, the area under the
curve ratio of 241 for doxorubicin documents the same
advantage.
4.2. Reduced Clearance of Intrapleural as Compared to Intra-
peritoneal Chemotherapy. In Figures 2 and 4, we calculated
the percent of the total dose of cancer chemotherapy instilled4 Gastroenterology Research and Practice
attime0thatwasabsorbedthroughthechestwallorthrough
the partially deﬂated lung into the body compartment. The
percent absorbed in 3 patients with HITOC mitomycin C
was compared to 25 patients with HIPEC mitomycin C.
Approximately half of the total quantity of mitomycin C
instilled escaped from the pleural cavity as compared to the
peritoneal cavity. Also, there was a reduction in the percent
of doxorubicin absorbed from the pleural space as compared
totheperitoneal space.Approximately 80%ofthe amount of
drugwasabsorbed fromthe pleural spaceas comparedto the
peritoneal cavity.
In the two drugs used for HITOC in which we performed
HPLC assays of chemotherapy concentration, both showed a
high area under the curve ratio of pleural ﬂuid to plasma.
This reduced clearance from the pleural space resulted
in a higher area under the curve ratio for intrapleural
mitomycin C or doxorubicin as compared to intraperitoneal
mitomycin C or doxorubicin. Our previous work with
mitomycin C showed that the area under the curve ratio
for intraabdominal treatment was approximately 27 [3]. It
was almost three times as large in this study with intrapleural
mitomycin C. The area under the curve ratio for intraperi-
toneal doxorubicin was approximately 79 [4]. Again, it was
more than three times greater with intrapleural doxorubicin
administration as compared to intrapleural instillation.
4.3. Speculations Regarding the Cause of Reduced Intrapleural
Chemotherapy Clearance. The Dedrick model for predicting
the clearance of intracavitary chemotherapy states that the
permeability of the surface combined with the total diﬀusion
surface controls the rate at which the concentration of a drug
within the body cavity tends to normalize with that in the
plasma [6]. A chest wall from which the pleura has been
completely removed may be less permeable to mitomycin
C and doxorubicin. Also, the partially deﬂated lung within
the chest cavity ﬁlled by chemotherapy solution will be
poorly perfused. Therefore, it may transmit drug less rapidly
away from the lung surface. Most probably, the perfusion
of the down lung is much less than the perfusion of the
visceraabsorbingandtransportingdrugwithintheabdomen
and pelvis. Also, the pleural space generally has a capacity
between1and1.5litersofchemotherapysolution.Theintra-
abdominal space has a 2-3 liter capacity for intraabdominal
chemotherapy. This lesser volume of chemotherapy would
result in a lesser total diﬀusion surface.
4.4. Possible Need for Further Phase I/II Studies. Upon the
initiation of our clinical experience with intrapleural chem-
otherapy, we considered an eﬀort to increase the concen-
tration of the intrapleural chemotherapy above that which
has been used for many years within the abdominal space.
However, two ﬁndings made it, we thought, unneces-
sary to perform further dose escalations. First of all, the
controlofpseudomyxomaperitoneiandperitonealmesothe-
lioma in the chest cavity following thoracic cytoreduction
and HITOC chemotherapy has approached 100%. Unpub-
lished data shows 30 patients treated to date with no recur-
rences recorded. Also important regarding dose escalation
is the morbidity and mortality seen with these studies.
Complicationsresultingfromparenchymallungdiseasehave
been noted in 3 of the 30 patients (10%). Two patients
developed pulmonary aspergillosis postoperatively and both
of these patients went on to die. Another patient developed
interstitialpneumonitis.Thisdidnotresultinherdemisebut
was a continuing problem in her limited survival. She died
as a result of progressive disease within the abdomen. As a
result of our clinical experience to date, further escalation
of the intrathoracic chemotherapy concentration does not
seem necessary. Our early clinical experience with thoracic
cytoreduction and intrathoracic chemotherapy has been
reported [1].
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